

PARADIGM BIOPHARMACEUTICALS LIMITED



ASX RELEASE

7 April 2020

PARADIGM TO HOST INVESTOR CALL TO DISCUSS US FDA REGULATORY PATHWAY, LATEST SAS REAL WORLD DATA AND CAPITAL RAISING PROCESS

Melbourne 7 April 2020, Paradigm Biopharmaceuticals Ltd (ASX: PAR): Paradigm is pleased to announce that it will **host a conference call at 8:30am (AEST) Wednesday 8th April** to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials.

Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7th April, with the company collating questions sent and will endeavour to answer the most frequently asked.

Questions are to be submitted to investorrelations@paradigmbiopharma.com

Teleconference Details

You are invited to participate in a conference call held by Paradigm Biopharmaceuticals Limited CEO, Paul Rennie.

The call is scheduled for 8:30am (AEST) Wednesday 8th April.
(US PST 3pm / EST 6 pm on Tuesday 7th; Hong Kong 6:30am).

Dial-in Details

Register for the call at the following link: <https://s1.c-conf.com/diamondpass/10005685-invite.html>

You will then be provided with the dial in number, the Passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

To join the conference, simply dial the number in the calendar invite and enter the passcode followed by your PIN, and you will join the conference instantly.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email : investorrelations@paradigmbiopharma.com